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ABSTRACT
CONTEXT AND OBJECTIVE: Over the last few years, different models for human skin equivalent reconstructed in vitro (HSERIV) have been reported for 
clinical usage and applications in research for the pharmaceutical industry. Before release for routine use as human skin replacements, HSERIV models 
need to be tested regarding their similarity with in vivo skin, using morphological (architectural) and immunohistochemical (functional) analyses. A model 
for HSERIV has been developed in our hospital, and our aim here was to further characterize its immunoarchitectural features by comparing them with 
human skin, before it can be tested for clinical use, e.g. for severe burns or wounds, whenever ancillary methods are not indicated. 
DESIGN AND SETTING: Experimental laboratory study, in the Skin Cell Culture Laboratory, School of Medical Sciences, Universidade Estadual de 
Campinas. 
METHODS: Histological sections were stained with hematoxylin-eosin, Masson’s trichrome for collagen fibers, periodic acid-Schiff reagent for basement 
membrane and glycogen, Weigert-Van Gieson for elastic fibers and Fontana-Masson for melanocytes. Immunohistochemistry was used to localize 
cytokeratins (broad spectrum of molecular weight, AE1/AE3), high molecular weight cytokeratins (34βE12), low molecular weight cytokeratins (35βH11), 
cytokeratins 7 and 20, vimentin, S-100 protein (for melanocytic and dendritic cells), CD68 (KP1, histiocytes) and CD34 (QBend, endothelium). 
RESULTS: Histology revealed satisfactory similarity between HSERIV and in vivo skin. Immunohistochemical analysis on HSERIV demonstrated that the 
marker pattern was similar to what is generally present in human skin in vivo. 
CONCLUSION: HSERIV is morphologically and functionally compatible with human skin observed in vivo.
RESUMO
CONTEXTO E OBJETIVO: Nos últimos anos, diferentes modelos de pele humana reconstruída in vitro (PHRIV) foram descritos para uso clínico e aplicações 
em pesquisa na indústria farmacêutica. Antes de serem liberados para uso rotineiro como substitutos de pele humana, os modelos de PHRIV necessitam 
de testes (estudos) comparativos com a pele humana in vivo, por meio de análises morfológica (arquitetural) e imunoistoquímica (funcional). O objetivo 
deste trabalho é estudar as características imunoistoquímicas de um modelo de PHRIV desenvolvido em nosso serviço, comparando-as com a pele 
humana, para que esse modelo de PHRIV possa vir a ser testado clinicamente em casos de queimaduras e ulcerações de pele nos quais métodos 
tradicionais de tratamento não estejam indicados.
TIPO DE ESTUDO E LOCAL: Estudo experimental laboratorial realizado no Laboratório de Cultura de Células da Pele da Faculdade de Ciências Médicas 
da Universidade Estadual de Campinas (FCM/Unicamp), Campinas, São Paulo, Brasil. 
MÉTODOS: Cortes histológicos foram corados com hematoxilina-eosina, tricrômio de Masson para fibras colágenas, ácido periódico-reagente de Schiff 
para membrana basal e glicogênio, Weigert-Van Gieson para fibras elásticas e Fontana-Masson para melanócitos. Estudo imunoistoquímico foi realizado 
para identificar citoqueratinas de amplo espectro de pesos moleculares (AE1/AE3), citoqueratinas de alto peso molecular (34βE12), citoqueratinas de 
baixo peso molecular (35βH11), citoqueratinas 7 e 20, vimentina, proteína S-100 (para melanócitos e células dendríticas), CD68 (KP1, histiócitos) e 
CD34 (QBend, endotélio). 
RESULTADOS: A histologia revelou similaridade satisfatória entre PHRIV e a pele in vivo. O estudo imunoistoquímico da PHRIV demonstrou padrão 
semelhante de marcadores usualmente presentes na pele humana in vivo. 
CONCLUSÃO: A PHRIV estudada é morfológica e funcionalmente compatível com a pele humana observada in vivo.
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INTRODUCTION
Over the last few years, different models for human skin equiv-
alent reconstructed in vitro (HSERIV) have been developed, con-
taining associations between dermis (or a dermal equivalent) and 
epidermis.1-6 These models represent an alternative system for test-
ing pharmacological products in the place of laboratory animals.7 
The European Union, through its “Sixth Amendment to the Europe-
an Community Cosmetic Directive”, has been aiming towards ban-
ning the use of animals in tests for certain types of cosmetic ingredi-
ents, combinations of ingredients and final products since January 1, 
1998.8 Furthermore, the skin substitutes obtained by tissue engineer-
ing nowadays represent an advanced therapeutic option for treating 
cutaneous lesions.9
The most recent approach, offering the best prospects for obtaining 
complex tissues in laboratories, is the use of biodegradable matrices as 
“models” to direct cell growth. These matrices are normally filled with 
live cells, derived from biopsies or from multipotent cells, that prolifer-
ate, organize and produce cellular and extracellular matrices. During the 
formation of cellular and extracellular matrices by the cells, the initially 
existing matrices are degraded, absorbed or metabolized.10
The following prerequisites are needed for a human skin equivalent 
to be used for scientific purposes:
•	 Formation	of	a	corneous	stratus	in vitro in the epidermis, thereby 
forming a mechanical barrier similar to the one found in vivo;
•	 Production	of	the	intracellular	lamellar	glycogen	corpuscles	that	are	
present in the granular layer of the epidermis;
•	 Lamellar	(cuticular)	appearance	for	the	epidermis.11
After meeting the scientific criteria and before the human skin 
equivalent can be used for studies or for clinical treatment in humans, it 
needs to be considered similar to human skin in vivo. One of the ways 
to obtain approval for the use of an in vitro human skin equivalent in 
people is to perform prior tests on animals. However, there is longstand-
ing concern12 about not using animals for laboratory tests and, as men-
tioned above, there are now moral and legal barriers against this.11 An-
other efficient method that does not cause moral or legal conflicts is to 
perform studies at the molecular and histochemical level on the human 
skin equivalents obtained.
Immunohistochemistry is a simple and widely used method for de-
tecting a number of cellular and extracellular antigens, either in fresh 
tissues and cells or in fixed paraffin-embedded specimens. These anti-
gens mostly correspond to protean filaments that are present in the cells, 
which may allow better understanding of the physiopathology of nor-
mal and diseased skin.13
In a previous study by our group, a specific model for HSERIV 
was reported.6 The resulting tissue consisted of an association of der-
mis and epidermis that was morphologically compatible with hu-
man skin in vivo. Our objective here was to functionally validate 
this skin model,6 through analysis of the tissue architecture and ex-
pression of specific protean markers of differentiation, with the aim 
of achieving acceptance for this human skin model for future use in 
clinical studies.
METHODS
This	study	was	performed	at	the	Skin	Cell	Culture	Laboratory	of	
the School of Medical Sciences, Universidade Estadual de Campinas 
(Unicamp),	Campinas,	São	Paulo,	Brazil.	The	technique	used	for	ob-
taining reconstructed human skin in vitro was the one described by Sou-
to et al.6 and it is summarized here.
After obtaining skin samples from patients who had undergone 
mammoplasty or abdominoplasty, cell cultures were performed in spe-
cific growth media for each cell type:
A. Culturing of epidermal epithelial cells in a culture medium for ke-
ratinocytes	 (Gibco	BRL,	Grand	Island,	New	York,	United	States,	
catalog number 10785-012);
B.	 Culturing	 of	melanocytes	 in	 a	 specific	 culture	medium	 (MCDB	
153;	Sigma	Chemical	Co.,	St.	Louis,	Missouri,	United	States,	code	
M-7403);
C. Culturing of fibroblasts in M199 culture medium (Gibco, catalog 
number 31100-035).
All	the	culture	media	were	supplemented	with	L-glutamine	(2	mM/
ml),	 penicillin	 (100	 IU/ml),	 streptomycin	 (0.1	mg/ml)	 (Gibco	BRL,	
Grand	 Island,	New	York,	United	States,	 catalog	number	10378-016)	
and 10% bovine fetal serum (Gibco, catalog number 10437-028). Epi-
dermal growth factor (5 ηg/ml)	(Gibco,	catalog	number	10450-013),	
bovine	 pituitary	 extract	 (50	 μg/ml)	 (Gibco,	 catalog	 number	 13028-
014),	hydrocortisone	(0.6	μg/ml)	(Sigma,	code	H-0888)	and	bovine	in-
sulin	(3	μg/ml)	(Gibco,	catalog	number	13007–018)	were	also	added	to	
the culture medium for keratinocytes.
After obtaining specific cultures for each cell type, fibroblasts were 
injected using a syringe, into a permeable and porous acellular mold 
(matrix) of bovine collagen type I, in block form (Gen-col, block col-
lagen,	code	961.25,	Genius	line,	Baumer	Biomaterials	Division,	Mogi	
Mirim,	São	Paulo,	Brazil),	measuring	approximately	10	x	15	x	25	mil-
limeters. The volume injected was 2.0 x 106 cells (fibroblasts), in M199 
culture medium (Gibco, catalog number 31100-035), supplemented 
with	 L-glutamine	 (2	 mM/ml),	 penicillin	 (100	 IU/ml),	 streptomycin	
(0.1	mg/ml)	(Gibco,	catalog	number	10378-0160)	and	10%	bovine	fe-
tal serum (Gibco, catalog number 10437-028). 
The collagen type I matrix containing fibroblasts was placed on a 
Petri	dish	of	 about	10.0	 cm2 and immersed in a culture medium for 
fibroblasts (M199; Gibco, catalog number 31100-035), supplement-
ed	with	L-glutamine	(2	mM/ml),	penicillin	(100	IU/ml),	streptomycin	
(0.1	mg/ml)	(Gibco,	catalog	number	10378-016)	and	10%	bovine	fetal	
serum (Gibco, catalog number 10437-028) and placed in an incubator 
at 37 °C, with CO
2
 tension of 5%.
The culture medium was changed three times a week. Reconstruct-
ed human dermis in vitro could be obtained in seven days. Epidermal 
cells (ratio between melanocytes and keratinocytes of 1:4) were grown 
on this human dermis reconstructed in vitro	on	the	Petri	dish,	mixed	
with 5.0 x 106 cells with about 1.0 x 106 melanocytes and 4.0 x 106 ke-
ratinocytes. The system was immersed in a culture medium for skin, 
formed by three parts of IMDM (Iscove’s Modified Dulbecco’s Medi-
um; Gibco, catalog number 12200-036) plus one part of culture me-
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dium for keratinocytes (Defined Keratinocyte Medium; Gibco, cata-
log number 10785-012), 10% bovine fetal serum (Gibco, catalog num-
ber	10437-028)	and	supplements	of	L-glutamine	(2	mM/ml),	penicil-
lin	 (100	 IU/ml),	 streptomycin	 (0.1	mg/ml)	 (Gibco,	 catalog	 number	
10378-016) and 1.5 mM Ca2+.
The culture medium was changed three times a week. HSERIV 
containing dermis and epidermis could be obtained in seven days (from 
the “ready” human dermis reconstructed in vitro). After obtaining the 
HSERIV composed of associated dermis and epidermis, it was subject-
ed to architectural (morphological) and immunohistochemical (func-
tional) analysis.
The HSERIV was fixed in 10% formalin and embedded in paraf-
fin. Histological sections of 4 μm in thickness were stained with hema-
toxylin-eosin (HE), Weigert-Van Gieson for elastic fibers, periodic acid-
Schiff	(PAS)	to	delineate	the	basement	membrane	and	Fontana-Masson	
silver impregnation to detect melanin pigmentation.
Immunohistochemical tests were performed using the following anti-
bodies:	anti-pan	cytokeratin	(AE1/AE3,	code	M3515;	diluted	at	1:100),	
high molecular weight cytokeratins (34βE12, code M0630; diluted at 
1:50), low molecular weight cytokeratins (35βH11, code M0631; dilut-
ed at 1:50), cytokeratin 7 (code M7018; diluted at 1:50), cytokeratin 20 
(code M7019; diluted at 1:50), vimentin (clone V9, code M0725; dilut-
ed at 1:100), S-100 protein (polyclonal, code Z0311; diluted at 1:1000), 
anti-CD68	(clone	KP1,	code	M0814;	diluted	at	1:100;	histiocytic	lin-
eage) and anti-CD34 (code M7165; diluted at 1:50; endothelial cells). 
All markers were obtained from DakoCytomation (Dako), Carpenteria, 
California, United States. All antibodies were diluted in 1% bovine se-
rum	albumin	(BSA)	in	phosphate	saline	buffer,	at	pH	7.6.
After deparaffination and hydration of the histological sections, 
they were then subjected to blocking of endogenous peroxidase, and an-
tigen recovery in a steamer (T-Fall, Dijon, France) with 10 mM citrate 
buffer at pH 6.0, at 90 °C for 30 minutes. The slides were incubated 
with the primary antibodies described above for 18 hours (overnight) at 
4 °C. The antigen-antibody binding was detected by means of the En-
Vision peroxidase system (code K1491; Dako). Staining was achieved 
using	3,3’-diaminobenzidine	(code	D-5637;	Sigma,	St.	Louis,	Missouri,	
United States) diluted in 3% H
2
O
2
	in	phosphate	saline	buffer	(PBS,	pH	
7.6). The positive controls consisted of skin fragments containing ne-
vocellular nevi. The same specimens were used as negative controls, by 
omitting the primary antibody and replacing it with incubation with 
PBS	buffer.	Positive	reactivity	was	shown	by	brown	staining	in	the	cyto-
plasm, as seen under an optical microscope.
The entire experiment was successfully performed in triplicate, in 
order to validate the analysis.
This investigation was approved by and conducted in accordance 
with the statements of the Research Ethics Committee of the School of 
Medical Sciences, Universidade Estadual de Campinas (Unicamp) and it 
complied with the Declaration of Helsinki, 1975, as amended in 1983.
RESULTS
The histological features of HSERIV have already been described 
elsewhere.6 Weigert-Van Gieson staining showed a small number of thin 
elastic	fibers	in	the	dermal	equivalent.	The	PAS	reaction	delineated	the	
basement membrane as a continuous thin layer between the epidermis 
and dermis. Fontana-Masson silver impregnation showed melanin pig-
mentation in scattered cells located in the basal layer, just above the 
basement membrane.
The immunohistochemical analysis on HSERIV showed that all the 
epithelial cells in all layers were strongly positive for pan cytokeratin 
AE1/AE3	and	for	high	molecular	weight	cytokeratins	(34βE12), as de-
scribed in normal epidermis. Scattered epithelial cells presented lower 
intensity of reaction to low molecular weight cytokeratins (35βH11) 
and cytokeratins 7 and 20 (Figure 1).
Mesenchymal markers were recognized in the underlying tissue: all 
dermal cells were strongly positive for vimentin, while a few scattered 
melanocytic cells stained for S100 protein. On the other hand, no his-
tiocytic or endothelial cells were found, as demonstrated with antibod-
ies for CD68 and CD34, respectively (Figure 2).
DISCUSSION
The stratification of the epidermis in the HSERIV presented char-
acteristics similar to what is found in vivo, although no formation of a 
real stratum spinosum was seen, and therefore the stratum corneum was 
extremely thin. The lack of formation of a real stratum spinosum in the 
epidermis of HSERIV models had already been reported in previous 
studies.14 The formation of a thin pellicle where the stratum corneum 
should be located might be due to the short period of time for which 
the newly formed epidermis remained exposed to the air-liquid inter-
face, as discussed by others.15
With regard to the extracellular matrix observed in the model that 
we developed,6 it seems possible that the bovine collagen was initially 
used by the human fibroblasts as a source of nutrition and also to regu-
late and orientate their growth. In a second stage, bovine collagen would 
be replaced by collagen from the injected fibroblasts, as accepted in oth-
er studies.1,4 The presence of only a few elastic fibers in the skin model, 
compared with normal skin (Weigert-Van Gieson staining), was prob-
ably due to the short time for which the cells remained in the culture 
medium, as mentioned earlier.15
The presence of a thin basement membrane in HSERIV (as seen via 
the	PAS	technique)	indirectly	demonstrates	the	formation	of	a	completely	
differentiated skin equivalent. As already stated, interactions between the 
epidermis and dermis, which are dependent on keratinocytes and dermal 
fibroblasts, are important for the production of laminin and collagen type 
IV (components of the basement membrane).16 In addition, the pigmen-
tation detected by Fontana-Masson silver impregnation corresponds to 
scattered melanin-producing cells, next to the basement membrane.
The use of immunohistochemical techniques to classify cell histo-
genesis is becoming more and more important, as the generation and 
application of skin equivalents grown in vitro are increasingly frequent-
ly achieved.17 These techniques are important for determining whether 
the cells present in skin equivalents in vitro correspond to the immune 
profile of cells from normal skin in vivo, before these equivalents can be 
used in research or therapeutics.18 A panel of immunomarkers is needed 
for better characterization of different proteins of the epithelium and 
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Figure 1. Immunohistochemical characterization of a human skin model reconstructed in vitro based on analysis of the cytokeratins present in epithelial 
cells. (A) Human skin reconstructed in vitro. Immunohistochemical analysis on anti-cytokeratin antibodies with a broad spectrum of molecular weights 
(AE1/AE3). Strong positive appearance in the epidermis (original magnifi cation 400 X). (B) Human skin reconstructed in vitro. Immunohistochemical 
analysis on anti-cytokeratin antibodies of high molecular weight (34βE12). Strong positive appearance in the epidermis (original magnifi cation 400 X). 
(C) Human skin reconstructed in vitro. Immunohistochemical analysis on anti-cytokeratin antibodies of low molecular weight (35βH11). Moderate to 
weak positive appearance in the epidermis (original magnifi cation 400 X). (D) Human skin reconstructed in vitro. Immunohistochemical analysis on anti-
cytokeratin antibody 7. Weak positive apperance in the epidermis (original magnifi cation 400 X).
mesenchyma, since they may differ according to function and the cell 
differentiation and maturation status.13
Up to now, 20 types of cytokeratins have been identifi ed‚19 with im-
portant functions as members of the cytoskeleton.13 The cytokeratins 
expressed in normal skin are of types 5 and 14 (basal layer of the epider-
mis), 1 and 10 (stratum spinosum) and 2 and 11 (stratum granulosum). In 
cases in which there is keratinocyte proliferation (e.g. psoriasis or heal-
ing), the cells of the suprabasal layer synthesize keratins 6 and 16.19,20
The AE1 antibody reacts with cytokeratins 10, 15, 16 and 19, and 
AE3 with cytokeratins 1, 2, 3, 4, 5, 6 and 8. A cocktail of both of these 
antibodies has been developed in order to react with a wide range of 
cytokeratins:	the	pan	cytokeratin	AE1/AE3.	The	antibody	to	high	mo-
lecular weight cytokeratins (34βE12) reacts with cytokeratins 1, 5, 10 
and 14, and the antibody to low molecular cytokeratins (35βH11) re-
acts with cytokeratins 8 and 18.19,21 Detection of cytokeratin 35βH11 is 
useful in determining the glandular nature of some tumors, such as ad-
enocarcinoma	and	Paget’s	disease.13 Cytokeratin 20 (CK20) is expressed 
in the gastric epithelium, urothelium, intestinal epithelium and Merkel 
cells of the skin.13 Detection of cytokeratin 7 is mainly achieved in pul-
monary, mammary, ovarian, endometrial and neuroendocrine tissues. 
In the skin, cytokeratin 7 may be expressed in basal cell carcinomas and 
trichoepitheliomas.22 A given type of epithelium or epithelial cell can 
be characterized by the specifi city of the cytokeratins expressed, and 
the cytokeratins produced by cultured cells (in vitro) are usually very 
similar to the cytokeratins expressed in normal tissues and in tumors.23 
In the present skin model, the most intense and extensive staining was 
achieved	with	AE1/AE3	and	34βE12, as is usually the case in normal 
skin. The presence of scattered cells that were less intensely positive for 
35βH11 and cytokeratins 7 and 20 may refl ect immaturity of some of 
the cells at the development stage at which they were studied.21,23
Melanocytes express S-100 protein, which was originally detected 
in glial cells.13 The polyclonal antibody to S-100 protein is routinely 
used to detect normal and altered melanocytes (melanomas), due to 
its high sensitivity.17 However, in the skin, antibodies to S-100 protein 
are	 not	 specifi	c	 for	melanocytes,	 since	 they	 can	 also	 identify	Langer-
hans and Schwann cells,17,24 sensory corpuscles and sudoriparous gland 
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Figure 2. Immunohistochemical characterization of a human skin model reconstructed in vitro based on analysis of mesenchymal cells. (A) Human skin 
reconstructed in vitro. Immunohistochemical analysis on anti-vimentin antibodies. Strong positive appearance in the dermis (original magnifi cation 400 
X). (B) Human skin reconstructed in vitro. Immunohistochemical analysis on anti-S-100 protein antibodies. Weak to moderate positive appearance in the 
epidermis (original magnifi cation 400 X). (C) Human skin reconstructed in vitro. Immunohistochemical analysis on negative anti-CD68 antibodies (original 
magnifi cation 400 X). (D) Human skin reconstructed in vitro. Immunohistochemical analysis on negative anti-CD34 antibodies (original magnifi cation 400 X).
cells.24 In our skin model, the topography of S-100-positive cells among 
basal cells, together with the detection of pigment by Fontana-Masson 
silver impregnation is consistent with their melanocytic origin.
In the skin, CD68 is present on the surface of macrophages and in 
Langerhans	cells,	while	in	other	types	of	tissue,	it	is	located	in	mono-
cytes and macrophages.25 The human progenitor cell antigen CD34 
is a surface antigen expressed by normal hematopoietic progenitors of 
the bone marrow. In normal skin, the expression of CD34 can be ob-
served in perivascular interstitial cells of the connective adventitial tissue 
and in the endothelium of blood vessels.13,26 The absence of CD68 and 
CD34 in our HSERIV was expected, since neither macrophages nor he-
matopoietic progenitor cells were added during the process of skin re-
construction in vitro. In addition, the skin equivalent described here did 
not contain blood vessels that could have been positive for CD34.
CONCLUSION
There is a clear similarity between the HSERIV presented here and 
human skin in vivo.	Neither	abnormalities	nor	evident	degenerative	al-
terations were seen in the cells, as demonstrated by morphological and 
immunohistochemical analyses. Our HSERIV may be considered to be 
similar to human skin in vivo	and	appropriate	for	laboratory/pharma-
ceutical or clinical and therapeutic studies. We believe that it may rep-
resent a promising substitute in cases of burns and chronic skin ulcers, 
with the aim of solving the problem of the need for large amounts of 
skin for transplantation in patients with scarce donor sites.
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